Engineering a HER2specific antibodydrug conjugate to increase lysosomal delivery and therapeutic efficacy httpsgo.nature.com2YGIRz2Âpic.twitter.comyj0U3z6TsU

Engineering a HER2-specific antibody–drug conjugate to increase lysosomal delivery and therapeutic efficacy https://go.nature.com/2YGIRz2 pic.twitter.com/yj0U3z6TsU

16:05 EDT 1 Apr 2019 | Nature Publishing

Engineering a HER2-specific antibodydrug conjugate to increase lysosomal delivery and therapeutic efficacy https://go.nature.com/2YGIRz2  pic.twitter.com/yj0U3z6TsU

More From BioPortfolio on "Engineering a HER2-specific antibody–drug conjugate to increase lysosomal delivery and therapeutic efficacy https://go.nature.com/2YGIRz2 pic.twitter.com/yj0U3z6TsU"